The FDA has approved Amgen’s Kyprolis for priority review for the treatment of patients with relapsed multiple myeloma who have already gone through one prior treatment.
The supplemental New Drug Application (or sNDA) for Kyprolis is based on the ENDEAVOR study.
Kyprolis is a drug used for the treatment of multiple myeloma. The drug became a part of Amgen’s oncology portfolio after the acquisition of Onyx Pharmaceuticals.
The Medicines Company (MDCO) fell marginally on December 14 by 0.45%. MDCO closed at $38.53 and was trading above the 100-day moving average.
Agios Pharmaceuticals (AGIO) has been on a downtrend since it presented data on AG-120 and AG-221. The stock has fallen more than 20% since December 4, 2015.
Ultragenyx Pharmaceutical (RARE) rebounded on December 14, 2015, after falling for four consecutive days. The stock rose 3.8% and was the top performer among the mid-cap stocks that day.
Incyte (INCY) was the top performer among large-cap stocks with a return of 2.8% on December 14. It rose on the announcement that INCY will present at the J.P. Morgan 34th Annual Healthcare Conference.
The iShares Nasdaq Biotechnology ETF (IBB) rose 0.3% on December 14, closing at $320.84. It traded 5% lower than the 100-day moving average of $337.86 and 3.1% lower than the 20-day moving average of $331.10.
Horizon Pharma fell by 5.2% for the week ending December 11. The stock fell as it announced the acquisition of Crealta Holdings for $510 million in cash.
Cerus (CERS) rose by 10.9% for the week. The stock rose because it signed several agreements for the use of INTERCEPT Blood System for platelets and plasma.
Anacor Pharmaceuticals (ANAC) was one of the top mid-cap performers for the week. It rose by 5.9% for the week. The stock rose due to good trading volumes.
When it comes to the individual stocks, Alexion Pharmaceuticals (ALXN) was the top performer. It had a return of 7% for the week ending December 11, 2015.
For the week ending December 11, most of the biotech stocks and ETFs were in the red. The SPDR S&P Biotech ETF (XBI) was the worst. It had a return of -6.5%.
Merck and Co.’s (MRK) Vytorin is a cholesterol drug that blocks the absorption of cholesterol from food and reduces the cholesterol made by the patient’s body naturally.
The IMPROVE-IT study was a randomized, double-blind trial of patients with acute coronary syndrome.
Merck and Co.’s Vytorin is a cholesterol medicine that blocks the absorption of cholesterol from food and reduces the cholesterol the patient’s body naturally produces.
Anacor Pharmaceuticals rose by by 8.6% on December 10, 2015. It closed at $118.74 and was trading at below its 100-day moving average price of $123.63.
Alexion Pharmaceuticals (ALXN) gained 2.5% on December 10, 2015. The stock went up after the FDA (Food and Drug Administration) approved its drug, Kanuma.
XBI closed at $68.15, trading 6.1% lower than the 100-day moving average price of $72.59 and 2.6% lower than the 20-day moving average price of $69.95.
Based on feedback from 20 brokers in a Bloomberg survey, 60% of brokers recommended “buy” and 40% recommended “hold” for Becton, Dickinson and Company.